Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Featured News

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

12/07/23  Vittoria Biotherapeutics has announced the clearance of an IND application with the U.S. FDA for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

Continue reading

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

05/03/23  Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics, Inc., a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Continue reading

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

11/07/22  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital.

Continue reading

Mission

  • To uncover and accelerate promising life science innovation
  • To enable talented entrepreneurs and innovators
  • To serve patients with unmet needs
Learn More

Investments

We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations that may otherwise lack the proper resources to progress efficiently.

Approach & portfolio